RPI 78

Drug Profile

RPI 78

Alternative Names: RPI-78

Latest Information Update: 20 Dec 2012

Price : $50

At a glance

  • Originator ReceptoPharm
  • Class Analgesics; Antirheumatics; Peptides
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain; Rheumatoid arthritis

Most Recent Events

  • 18 Dec 2012 Discontinued - Phase-I for Pain in USA (Parenteral)
  • 18 Dec 2012 Discontinued - Phase-I for Rheumatoid arthritis in USA (Parenteral)
  • 26 Jul 2010 Phase-I clinical trials in Pain in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top